Short-term follow-up
Barrett, Barrett’s metaplasia
BARRETT
In accordance with the protocol, follow-up examinations were planned 3 and 6 months after the last ablative therapy. Seventy-four patients (RFA: In the RFA and H-APC groups, Barrett’s metaplasia was diagnosed in 35.5% (11/31) and 20.9% (9/43) of the patients, respectively. Patients with macroscopically minimal residual Barrett’s at the neo-Z line, but negative findings at histology were counted as eradicated for Barrett.In summary, the rates of Barrett’s eradication during the short-term follow-up were 64.5% (20/31) in the RFA arm and 79.1% (34/43) in the H-APC arm.